April 2014
Volume 55, Issue 13
ARVO Annual Meeting Abstract  |   April 2014
Evaluation of the Onset and Duration of Action of Topical Cetirizine (AC-170 0. 24%) for the Prevention of Allergic Conjunctivitis
Author Affiliations & Notes
  • Paul J Gomes
    Allergy, ORA, Andover, MA
  • Yesha Raval
    Allergy, ORA, Andover, MA
  • Emily Schoemmell
    Allergy, ORA, Andover, MA
  • Donna L Welch
    Ora, Inc, Andover, MA
  • Footnotes
    Commercial Relationships Paul Gomes, Ora, Inc (E); Yesha Raval, Ora, Inc (E); Emily Schoemmell, Ora, Inc (E); Donna Welch, Ora, Inc (E)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science April 2014, Vol.55, 2490. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Paul J Gomes, Yesha Raval, Emily Schoemmell, Donna L Welch; Evaluation of the Onset and Duration of Action of Topical Cetirizine (AC-170 0. 24%) for the Prevention of Allergic Conjunctivitis. Invest. Ophthalmol. Vis. Sci. 2014;55(13):2490.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: : In this phase 3, multicenter, vehicle-controlled, double-blinded, randomized trial we evaluated the onset and duration of action of topical cetirizine 0.24% using the conjunctival allergen challenge model of allergic conjunctivitis.

Methods: The trial (NCT01881113) was conducted between June and September of 2013, and enrolled a total of 101 subjects; this number constituted the intent-to-treat and safety populations, while the per-protocol population included 87 subjects. Qualified subjects exhibited reproducible allergic responses to bilateral instillation of allergen. Following randomization, they were challenged with allergen on 2 separate visits, 15 minutes or 8 hours after receiving bilateral instillation of test compound or vehicle. Primary efficacy measures were ocular itching scores (at 3, 5, and 7 minutes post-challenge) and ocular hyperemia (at 7, 15, and 20 minutes post-challenge). Secondary endpoints included ciliary and episcleral redness, chemosis, eyelid swelling, and ear/palate pruritis; each of these were scored at 7, 15, and 20 minutes post challenge.

Results: For the primary endpoint of ocular itching, Cetirizine was statistically superior to vehicle for the onset of action (challenge 15 minutes post-instillation; p < 0.0001) at all measured time points; the drug was also statistically superior to vehicle 8 hours after instillation (p < 0.0001). In a subgroup analysis, the drug exhibited highest efficacy in those subjects with the most severe baseline itch scores. Cetirizine was superior to vehicle for all secondary endpoints, including all measures of hyperemia. Of particular note, drug treatments were statistically superior to vehicle for prevention of eyelid swelling and ear/palate pruritis at all measured time points (p< 0.001), suggesting a unique spectrum of efficacy. The study drug was safe and well tolerated; no subjects withdrew from the study due to any adverse event.

Conclusions: Cetirizine is one of the most commonly used oral agents for treatment of allergic rhinitis, but its re-formulation for topical use in treatment of allergic conjunctivitis is novel. This study demonstrates the efficacy of the drug for prevention of ocular itching associated with allergic conjunctivitis, and also establishes its unique spectrum of action against other allergic symptoms.

Keywords: 475 conjunctivitis • 557 inflammation • 466 clinical (human) or epidemiologic studies: treatment/prevention assessment/controlled clinical trials  

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.